Project Grant R01AI184710
Award Date
6/7/24
Completion Date
5/31/29
Dollars Obligated
$777K
Federal Agency
National Institute of Allergy and Infectious Diseases
Federal Grant Program
93.855
Assistance Type
Project Grant
Place of Performance
Lexington, KY 40536, USA
Similar Awards
This Project Grant award, totaling $648,448.00, was provided by the National Institute of Allergy and Infectious Diseases (NIAID) under the Allergy and Infectious Diseases Research program (CFDA 93.855). The funding supports research to define the complex genetic basis of Plasmodium falciparum resistance to artemisinin and quinine, as well as identify resistance-refractory therapeutics. Specifically, the research aims to: Investigate the role of candidate genes MRP1 and ARPS10 in mitigating...
This $467,400 Project Grant from the National Institute of Allergy and Infectious Diseases (NIAID), under the Allergy and Infectious Diseases Research program (CFDA 93.855), aims to develop a platform for quantifying levels of antimalarial drugs, including lumefantrine, amodiaquine, and piperaquine, in dried blood spot (DBS) samples. The research team at the University of California, San Francisco (UCSF) will employ volumetric absorptive microsampling (VAMS) techniques to collect precise DBS...
This $587,318 Project Grant award from the National Institute of Allergy and Infectious Diseases (NIAID), under the Allergy and Infectious Diseases Research program (CFDA 93.855), supports research to optimize the structural features of the anti-malarial drug candidate ELQ-596. The goal is to develop a next generation of ELQ compounds for once-monthly oral prophylaxis against malaria in humans. The research team at Oregon Health & Science University (OHSU) will assess the selective...
This $400,347 Project Grant award from the National Institute of Allergy and Infectious Diseases (NIAID) under the Allergy and Infectious Diseases Research program (CFDA 93.855) supports research to profile malarial lipid biosynthesis and key acyl-coenzyme A synthetase activities in the malaria parasite Plasmodium falciparum. The two-year project, running from July 2024 to May 2026, will develop a new "fatty acid alkyne profiling" approach to systematically analyze fatty acid uptake...
This federal Project Grant award from the National Institute of Allergy and Infectious Diseases (NIAID), under the Allergy and Infectious Diseases Research program (CFDA 93.855), provides $206,116 to Oregon Health & Science University (OHSU) to develop new 4-aminoquinoline compounds as potential therapeutics against multi-drug resistant Plasmodium falciparum, the deadliest malaria parasite. The key objectives are to: 1) use an iterative medicinal chemistry approach to optimize the lead...
This Project Grant award from the National Institute of Allergy and Infectious Diseases (NIAID), under the Allergy and Infectious Diseases Research (CFDA 93.855) program, provides $1,553,810 to the University of Maryland, Baltimore to conduct genomic surveillance for artemisinin resistance in Africa. The project aims to evaluate a genomic surveillance approach to identify mutations and altered biological functions in Plasmodium falciparum that confer resistance to artemisinin-based combination...
This Project Grant award of $1,373,790 from the National Institute of Allergy and Infectious Diseases (CFDA 93.855 - Allergy and Infectious Diseases Research) aims to optimize the structural features of the antimalarial drug candidate ELQ-596 to develop a next generation of ELQ compounds for once-monthly oral malaria prophylaxis in humans. The primary awardee, Oregon Health & Science University, will lead this research effort in collaboration with Drexel University and the Portland VA...
This $1,480,500 federal Project Grant award from the National Institutes of Health (NIH) Office of the Director under the Trans-NIH Research Support program (CFDA 93.310) is funding a research project to investigate the role of non-coding RNAs in regulating artemisinin-resistant malaria parasite quiescence. The project aims to identify and functionally characterize long non-coding RNAs and tRNA-derived fragments that enable Plasmodium falciparum parasites to enter and exit drug-induced quiescent...
This federal Project Grant award from the National Institute of Allergy and Infectious Diseases (NIAID), under the Allergy and Infectious Diseases Research program (CFDA 93.855), is focused on deciphering artemisinin resistance in Plasmodium falciparum malaria in Bangladesh. The USD 997,688 award supports a 2-year research project to investigate the molecular determinants of artemisinin resistance, including those independent of the K13 gene mutation. The key objectives are to perform...
This $949,200 Project Grant award from the National Institute of Allergy and Infectious Diseases (CFDA 93.855 - Allergy and Infectious Diseases Research) supports research to investigate the mechanisms underlying severe malarial anemia. The study aims to determine whether elevated levels of the enzyme xanthine oxidase (XO) contribute to the loss of uninfected red blood cells, a major factor in malaria-induced anemia. The research will examine the effects of XO from patient plasma on the...